Oxypertine in tardive dyskinesia: an 8-week controlled study

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Tardive dyskinesia is a movement disorder often associated with antipsychotic medication.
• Chronic schizophrenia patients frequently experience tardive dyskinesia.
• Effective treatment options for tardive dyskinesia are needed.

Purpose of the Study:

• To evaluate the efficacy of oxypertine in treating tardive dyskinesia.
• To compare oxypertine's effectiveness against a placebo in patients with chronic schizophrenia.

Main Methods:

• A double-blind, placebo-controlled trial was conducted.
• Thirty-three patients diagnosed with chronic schizophrenia participated.
• Participants received either oxypertine or a placebo for eight weeks.

Main Results:

• Oxypertine demonstrated statistically significant superiority over placebo.
• The study observed a notable improvement in tardive dyskinesia symptoms with oxypertine treatment.

Conclusions:

• Oxypertine is a promising therapeutic agent for tardive dyskinesia.
• The findings support the use of oxypertine in managing antipsychotic-induced movement disorders.